Bridgeway Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bridgeway Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,200	Closed	-$505K	–	1380
2024 Q1	$505K	Hold	34,200	–	–	0.01%	922
2023 Q4	$459K	Hold	34,200	–	–	0.01%	960
2023 Q3	$422K	Hold	34,200	–	–	0.01%	927
2023 Q2	$421K	Hold	34,200	–	–	0.01%	956
2023 Q1	$420K	Hold	34,200	–	–	0.01%	923
2022 Q4	$392K	Hold	34,200	–	–	0.01%	944
2022 Q3	$128K	Sell	34,200 -25,000	-42%	-$115K	﹤0.01%	1228
2022 Q2	$352K	Hold	59,200	–	–	0.01%	961
2022 Q1	$374K	Hold	59,200	–	–	0.01%	1015
2021 Q4	$231K	Hold	59,200	–	–	﹤0.01%	1139
2021 Q3	$286K	Hold	59,200	–	–	0.01%	1164
2021 Q2	$378K	Sell	59,200 -5,000	-8%	-$33K	0.01%	1149
2021 Q1	$403K	Buy	64,200 +2,500	+4%	+$17.9K	0.01%	1155
2020 Q4	$425K	Hold	61,700	–	–	0.01%	1008
2020 Q3	$247K	Hold	61,700	–	–	0.01%	1131
2020 Q2	$205K	Hold	61,700	–	–	﹤0.01%	1147
2020 Q1	$133K	Hold	61,700	–	–	﹤0.01%	1140
2019 Q4	$194K	Hold	61,700	–	–	﹤0.01%	1200
2019 Q3	$277K	Sell	61,700 -16,721	-21%	-$83.6K	﹤0.01%	1113
2019 Q2	$373K	Buy	78,421 +44,485	+131%	+$211K	﹤0.01%	1050
2019 Q1	$186K	Buy	+33,936	New	+$156K	﹤0.01%	1232
2018 Q4	–	Sell	-80,327	Closed	-$337K	–	1537
2018 Q3	$337K	Hold	80,327	–	–	﹤0.01%	1228
2018 Q2	$310K	Buy	+80,327	New	+$533K	﹤0.01%	1242

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bridgeway Capital Management's MACK Position: Q2 2024 in Review

Bridgeway Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 34,200 shares — an estimated $505K sold.

Bridgeway Capital Management first reported a position in MACK in Q2 2018 and held it in 23 quarters. The position peaked at $505K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Bridgeway Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Bridgeway Capital Management sold 34,200 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $505K.
Bridgeway Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 23 quarters.
Bridgeway Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $505K in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.